ABBISKO-B (02256) announced its annual results for the year ended December 31, 2025. The group recorded revenue of RMB 612 million, representing a year-on-year increase of 21.45%. Total comprehensive income attributable to owners of the parent was RMB 23.698 million, a decrease of 53.46% compared to the previous year. Basic earnings per share stood at RMB 0.09. This marks the second consecutive year of profitability for the company. For the year ended December 31, 2025, the group achieved revenue of RMB 612.1 million, primarily derived from licensing income received from Merck, with a profit of RMB 55.2 million.

The company repurchased shares to enhance market confidence and shareholder value. On March 3, 2025, the board approved a share repurchase plan with a maximum value of HKD 200 million. During the fiscal year ended December 31, 2025, the company repurchased a total of 10.229 million shares, representing 1.51% of the total shares issued as of January 1, 2025, for a total consideration of HKD 84.7 million. In the previous year, 2024, the company also repurchased 22.594 million shares for a total amount of HKD 68.7 million.

ABBISKO-B maintains a strong cash position. As of December 31, 2025, cash and bank balances, including term deposits over three months and cash equivalents, amounted to RMB 2.027 billion. This represents an increase of RMB 67.8 million from the RMB 1.9592 billion reported on December 31, 2024. The growth in cash reserves was primarily driven by the receipt of licensing income and an increase in interest-bearing bank borrowings.